Prevention of fibrosis in experimental colitis by captopril: The role of tgf-β1

Inflammatory Bowel Diseases

Volumn 10, Issue 5, 2004, Pages 536-545

  Wengrower, Dov ^a   Zannineli, Giuliana ^a,c   Pappo, Orit ^a   Latella, Giovanni ^c   Sestieri, Mirna ^a   Villanova, Amancay ^a   Faitelson, Yoram ^a   Pines, Mark ^b   Goldin, Eran ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b VOLCANI CENTER   (Israel)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Captopril; Crohn's disease; Experimental colitis; Fibrosis; TGF 1

Indexed keywords

ANGIOTENSIN; CAPTOPRIL; COLLAGEN TYPE 1; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYPROLINE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC INFLAMMATION; COLITIS; CONTROLLED STUDY; DATA ANALYSIS; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; INTESTINAL FIBROSIS; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN FUNCTION; RAT; TISSUE LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; COLITIS; COLON; DISEASE MODELS, ANIMAL; FIBROSIS; MALE; RATS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 4644308778     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200409000-00007     Document Type: Article

References (71)

1. Agarwal R, Siva S, Dunn SR, et al. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis. 2002;39:486-492.
2. Ashcroft GS, Yang X, Glick A, et al. Mice lacking Smad3 show accelarated wound healing and impaired local inflammatory response. Nat Cell Biol. 1999;1:260-266.
3. Asplund S, Gramlich TL. Chronic mucosal changes of the colon in graft-versus-host disease. Mod Pathol. 1998;11:513-515.
4. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factor α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology. 1996;110:975-984.
5. Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflammatory Bowel Disease. 1999;5:44-60.
6. Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. L Exp Med. 1998;188:1929-1939.
7. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292.
8. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
9. Buyuukgebiz O, Aktan AO, Yegen C, et al. Captorpil increases endothelin serum concentrations and preserves intestinal mucosa after mesenteric ischemia reperfusion injury. Res Exp Med. 1994;194:339-348.
10. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947-1958.
11. Dammeier J, Brauchle M, Falk W, et al. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int J Biochem Cell Biol. 1998;30:909-922.
12. Di Mola F, Friess H, Scheuren A, et al. Transforming growth factor-βs and their signaling receptors are co expressed in Crohn's disease. Ann Surg. 1999;229:67-75.
13. de Cavanagh EM, Inserra F, Ferder L, et al. Enalapril and captopril enhance glutathione-dependent antioxidant defences in mouse tissues. Am J Physiol Regal Integr Comp Physiol. 2000;278:R572-R577.
14. Desreumaux P, Huet G, Zerimech F, et al. Acute inflammatory intestinal vascular lesions and in situ abnormality of the plasminogen activation system in Crohn's disease. Eur J Gastroenterol Hepatol. 1999;11:1113-1119.
15. Desreumaux P, Bloget F, Seguy D, et al. Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. Gastroenterology. 1996;110:768-774.
16. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
17. Fiocchi C. TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J Clin Invest. 2001;108:523-526.
18. Fukuda N, Hu WY, Kubo A, et al. Angiotensin II upregulates transforming growth factor-beta I receptor on rat vascular smooth muscle cells. Am J Hypertens. 2000;13:191-198.
19. Gavish Z, Pinthus JH, Barak V, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate. 2002;51:73-83.
20. Godfrey K. Statistic in practice. N Engl J Med. 1985;313:1450-1456.
21. Gorelik L, Flavel RA. Abrogation of TGF-beta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity. 2000;12:171-181.
22. Griga T, Voigt E, Gretzer B, et al. Increased production of vascular endotelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology. 1999;46:920-923.
23. Jaszewski R, Tolia V, Ehrinpreis MN, et al. Increased colonic mucosal angiotensin I and II concentration in Crohn's colitis. Gastroenterology. 1990;98:1543-1548.
24. Jonsson JR, Clouston AD, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148-155.
25. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, Basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol. 2001;96:822-828.
26. Kitani A, Fuss IJ, Nakamura K, et al. Treatment of experimental (trinitrobenzene sulphonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid: TGF-β1-mediated suppresion of T helper cells type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor β2 chain downregulation. J Exp Med. 2000;192:41-52.
27. Kopp JB, Factor VM, Mozes M, et al. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab Invest. 1996;74:991-1003.
28. Krüse JJCM, Bart CI, Leer JWH, et al. Detection and quantitative measurement of TGF-β gene expression using a seminested competitive PCR assay. Cytokine. 1999;11:179-185.
29. Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta 1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis. 2001;7:16-26.
30. Lawrance IC, Maxwell L, Doe W. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokine in inflammatory bowel disease. Inflamm Bowel Dis. 2001;7:226-236.
31. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverse myocardial fibrosis in a transgenic mous model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791.
32. Logan A, Berry M. Transforming growth factor-beta 1 and basic fibroblast growth factor in the injured CNS. Trends Pharmacol Sci. 1993;14: 337-342.
33. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol. 1997;159:3622-3628.
34. Matsusaka T, Hymes J, Ichkawa I. Angiotensin in progressive renal diseases: Theory and practice. J Am Soc Nephrol 1996;7:2025-2043.
35. Mansour M, Agha A. Inhibition of calcium ionophore-stimulated leukotriene generation from intact human neutrophils by captopril. Res Commun Mol Pathol Pharmacol. 1999;104:345-360.
36. McKaing BC, Hughes K, Tighe PJ, et al. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:C172-C182.
37. McKay S, de Jongste JC, Saxena PR, et al. Angiotensin II induces hypertrophy of human airway smooth muscle cells: expression of transcription factors and transforming growth factor-beta1. Am J Respir Cell Mol Biol. 1998;18:823-833.
38. Molteni A, Moulder JE, Cohen EF, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blocker. Int J Radiat Biol. 2000; 76:523-532.
39. Monteleone G, Kumberova A, Croft NM, et al. Blocking Smad7 restores TGFβ1 signaling in chronic inflammatory bowel disease. J Clin Invest. 2001;108:601-609.
40. Morris JP, Beck PL, Herridege MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.
41. Mourelle M, Salas A, Guarner F, et al. Stimulation of transforming growth factor beta-1 by enteric bacteria in the pathogenesis of rat intestinal fibrosis. Gastroenterology. 1998;114:519-526.
42. Murthy SNS, Cooper HS, Shim H, et al. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci. 1993;38:1722-1734.
43. Nakao A, Miike S, Hatznom, et al. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. 2000;192:151-158.
44. Neurath MF, Fuss I, Kelsall BL, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated tolerance. J Exp Med. 1996;183:2605-2616.
45. Neurath M, Fuss I, Strober W. TNBS colitis. Int Rev Immunol. 2000;19: 51-62.
46. Oikawa T, Freeman M, Lo W, et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51:164-172.
47. Pawlak R, Chabielska E, Marys T, et al. Thiol repletion prevents venous thrombosis in rats by nitric oxide/prostacyclin-dependent mechanism: relation to the antithrombotic action of captopril. J Cardiovasc Pharmacol. 2000;36:503-509.
48. Perr H, Oh P, Johnson D. Developmental regulation of transforming growth factor beta-mediated collagen synthesis in human intestinal muscle cells. Gastroenterology. 1996;110:92-101.
49. Peeters AC, Netea MG, Kullberg BJ, et al. The effect of renin-angiotensin system inhibitors on pro- and anti inflammatory cytokine production. Immunology. 1998;94:376-379.
50. Peters H, Border WA, Noble N. Targeting TGF-β1 over expression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 1998;54:1570-1580.
51. Podolsky DK. Review article: healing after inflammatory injury-coordination of a regulatory peptide network. Aliment Pharmacol Ther. 2000;14(Suppl 1):87-93.
52. Powrie F, Carlino J, Leach MW, et al. A critical role of transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4+ cells. J. Exp. Mrd. 1996;183: 2669-2674.
53. Roberts AB. Molecular and cell biology of TGF-β. Miner Electrolyte Metab. 1998;24:111-119.
54. Sanderson N, Factor V, Nagy P, et al. Hepatic expression of mature transforming growth factor-b1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A. 1995;92:2572-2576.
55. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates the hyperthrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787-796.
56. Shin GT, Kim SJ, Ma KA, et al. ACE inhibitors attenuate expression of renal transforming growth factor-beta1 in humans. Am J Kidney Dis. 2000;36:894-902.
57. Shah M, Foreman DM, Ferguson MW. Neutralizing antibody to TGF-β2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994;107:1137-1157.
58. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 1992;359:693-699.
59. Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-β induces prolonged severe fibrosis in the lung. J Clin Invest. 1997;100:768-776.
60. Simon HM, Christian PB, William CS, et al. High endothelin-1 immunoreactivity in Crohn's disease and ulcerative colitis. It J Gastroenterol Hepatol. 1998;30:266-269.
61. Stagemann H, Stader K. Determination of hydroxyproline. Clin Chim Acta. 1967;18:267-273.
62. Stahle-Backdahl M, Malm J, Veress B, et al. Increased presence of eosinophilic granulocytes expressing transforming growth factor-β1 in collagenous colitis. Scand J Gastroenterol. 2000;35:742-746.
63. Sun Y, Zhang J, Zhang JQ, et al. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension. 2000;35:1078-1084.
64. Tahashi W, Matsuzaki K, Date M, et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology. 2002;35:49-61.
65. Tzanidis A, Lim S, Hannan RD, et al. Combined angiotensin and endothelin receptor blockade attenuate adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta 1. J Mol Cell Cordiol. 2001;35:969-981.
66. Wang J, Zheng H, Sung CC, et al. Cellular sources of transforming growth factor-beta isoforms in early and chronic radiation enteropathy. Am J Pathol. 1998;153:1531-1540.
67. Ward WF, Molteni A, Tsfao C, et al. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Phys. 1990; 19:1405-1409.
68. Weber P, Husemann S, Vielhaber H, et al. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1999;28:418-422.
69. Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of Smad3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 1999;18:1280-1291.
70. Yoshiji H, Kuriyama S, Yoshiji J, et al. Angiotensin II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745-750.
71. Zaoui P, Cantin JF, Alimardani-Bessette M, et al. Role of metalloproteases and inhibitors in the recurrence and progression of diabetic renal lesions. Diabetes Metab. 2000;26:25-29.